BioMarin Pharmaceutical Inc (HAM:BM8) Stock Price, Trades & News

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.

Financial Strength

8/10

Name	Current	Vs Industry
Cash-To-Debt	1.54
Equity-to-Asset	0.72
Debt-to-Equity	0.23
Debt-to-EBITDA	2.98
Interest Coverage	13.71
Piotroski F-Score	5/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	3.99	Distress Grey Safe
Beneish M-Score	-2.8	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

10/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	13.7
	3-Year EBITDA Growth Rate	27.4
	3-Year EPS without NRI Growth Rate	138.9
	3-Year FCF Growth Rate	149.1
	3-Year Book Growth Rate	8.6
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	54.01
	Future 3-5Y Total Revenue Growth Rate Estimate	14.5

Momentum Rank

2/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	61.08
	9-Day RSI	60.67
	14-Day RSI	59.53
	3-1 Month Momentum %	3.53
	6-1 Month Momentum %	-3.99
	12-1 Month Momentum %	45.48

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	5.81
	Quick Ratio	4.2
	Cash Ratio	2.8
	Days Inventory	630.27
	Days Sales Outstanding	94.5
	Days Payable	163.34

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-1.1
	Shareholder Yield %	-0.76

Profitability Rank

5/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	76.53
	Operating Margin %	9.72
	Net Margin %	8.29
	EBITDA Margin %	14.88
	FCF Margin %	23.4
	OCF Margin %	26.94
	ROE %	4.45
	ROA %	3.5
	ROIC %	3.95
	3-Year ROIIC %	30.54
	ROC (Joel Greenblatt) %	15.58
	ROCE %	5.88
	Years of Profitability over Past 10-Year	5
	Moat Score	7
	Tariff Resilience Score	7

GF Value Rank

4/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	43.15
	Forward PE Ratio	16.66
	PE Ratio without NRI	21.27
	Price-to-Owner-Earnings	95.97
	PEG Ratio	0.33
	PS Ratio	3.58
	PB Ratio	1.84
	Price-to-Tangible-Book	1.97
	Price-to-Free-Cash-Flow	15.2
	Price-to-Operating-Cash-Flow	13.21
	EV-to-EBIT	26.05
	EV-to-Forward-EBIT	17.31
	EV-to-EBITDA	22.06
	EV-to-Forward-EBITDA	14.53
	EV-to-Revenue	3.28
	EV-to-Forward-Revenue	2.75
	EV-to-FCF	14.02
	Price-to-GF-Value	0.67
	Price-to-Projected-FCF	1.47
	Price-to-Median-PS-Value	0.42
	Price-to-Peter-Lynch-Fair-Value	0.85
	Price-to-Graham-Number	1.36
	Price-to-Net-Current-Asset-Value	5.13
	Earnings Yield (Greenblatt) %	3.84
	FCF Yield %	6.64
	Forward Rate of Return (Yacktman) %	22.78

Financials (Next Earnings Date:2026-08-04 Est.)

Annual Quarterly TTM

HAM:BM8's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

BioMarin Pharmaceutical Inc Executives

Details

GF Value™: €77.85

HAM:BM8

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 3 Medium warning signs with BM8. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	2,786.544
	EPS (TTM) (€)	1.192
	Beta	0.154
	3-Year Sharpe Ratio	0.52
	3-Year Sortino Ratio	2.07
	Volatility %	43.93
	14-Day RSI	59.53
	14-Day ATR (€)	1.013955
	20-Day SMA (€)	49.799
	12-1 Month Momentum %	45.48
	52-Week Range (€)	34.265 - 54.1
	Shares Outstanding (Mil)	193.28

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	5
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

BioMarin Pharmaceutical Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

BioMarin Pharmaceutical Inc Stock Events

Financials Calendars

Event	Date	Price (€)
Third quarter earnings conference call for 2026	2026-10-27 16:30	In 108 days
Third quarter earnings results for 2026	2026-10-27	In 107 days
Second quarter earnings conference call for 2026	2026-08-04 16:30	In 24 days
Second quarter earnings results for 2026	2026-08-04	In 23 days
General meeting for 2026	2026-06-02 11:30	48.46 (+0.00%)
First quarter earnings conference call for 2026	2026-05-04 16:30	46.32 (+0.00%)
First quarter earnings results for 2026	2026-05-04	46.32 (+0.00%)
Barclays 28th Annual Global Healthcare Conference	2026-03-11 14:00	52.00 (+0.00%)
Guidance call for 2026	2026-03-09 08:00	51.46 (+0.00%)
TD Cowen 46th Annual Health Care Conference	2026-03-04 10:30	49.78 (+0.00%)

Show

Entries

BioMarin Pharmaceutical Inc Frequently Asked Questions

What is BioMarin Pharmaceutical Inc(HAM:BM8)'s stock price today?

The current price of HAM:BM8 is €52.24. The 52 week high of HAM:BM8 is €54.10 and 52 week low is €34.27.

When is next earnings date of BioMarin Pharmaceutical Inc(HAM:BM8)?

The next earnings date of BioMarin Pharmaceutical Inc(HAM:BM8) is 2026-08-04 Est..

Does BioMarin Pharmaceutical Inc(HAM:BM8) pay dividends? If so, how much?

BioMarin Pharmaceutical Inc(HAM:BM8) does not pay dividend.

Press Release

	Subject	Date
	BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026	2026-06-16
	BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia	2026-05-20
	BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency	2026-05-18
	BioMarin Completes Acquisition of Amicus Therapeutics	2026-04-27
	BioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET	2026-04-27
	BioMarin Announces Board Leadership Transition	2026-04-21
	U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU)	2026-02-27
	BioMarin to Participate in Four Upcoming Investor Conferences in March	2026-02-24
	BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results	2026-02-23
	BioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4:30pm ET	2026-02-17

10/Page

Articles on BioMarin Pharmaceutical Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.